» Articles » PMID: 34056682

Interstitial Lung Disease with Myeloperoxidase-antineutrophil Cytoplasmic Antibody-associated Vasculitis in Elderly Patients

Abstract

Anti-neutrophil cytoplasmic antibodies-associated vasculitis (AAV) occurs in elderly people, and patients with anti-myeloperoxidase autoantibodies (MPO-ANCA)-positive AAV are often complicated with interstitial lung disease (ILD). This study aimed to evaluate the age-related clinical features of elderly patients with MPO-ANCA-positive AAV-ILD. This study retrospectively investigated 63 patients with MPO-ANCA-positive AAV-ILD, all of whom were 65 years or older at diagnosis. Clinical characteristics, causes of death and survival rates among three groups stratified by age (65-74 years, n = 29; 75-79 years, n = 18; over 80 years, n = 16) were compared. This study also examined the association with severe infections in these patients. Among the three age groups, there were significant differences in sex (P = 0.032), serum Krebs von den Lungen-6 (P < 0.01), and total ground-glass opacity score (P = 0.011). The causes of death were mainly severe infections and complications of ILD. Kaplan-Meier curve analysis showed a significantly lower 5-year survival rate in the oldest group (P < 0.01). Regarding severe infections in these patients, the 5-year cumulative incidence of severe infections was higher in the patients receiving steroid pulse therapy (P = 0.034). The clinical characteristics of MPO-ANCA-positive AAV-ILD differ with age in elderly patients, with age being an important poor prognostic factor in these patients. The administration of steroid pulse therapy is a significant risk factor of severe infection in MPO-ANCA-positive elderly patients with AAV-ILD.

Citing Articles

Clinical Profiles, Survival, and Lung Function Outcomes in ANCA-Associated Interstitial Lung Disease: An Observational Study.

Valero-Martinez C, Valenzuela C, Baldivieso Acha J, Martinez-Besteiro E, Quiroga-Colina P, Alfranca A J Clin Med. 2025; 14(1.

PMID: 39797313 PMC: 11722352. DOI: 10.3390/jcm14010229.


Presentation and progression of MPO-ANCA interstitial lung disease.

Salvati L, Palterer B, Lazzeri E, Vivarelli E, Amendola M, Allinovi M J Transl Autoimmun. 2024; 8:100235.

PMID: 38445024 PMC: 10912625. DOI: 10.1016/j.jtauto.2024.100235.


Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review.

Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T J Clin Med. 2022; 11(13).

PMID: 35807120 PMC: 9267459. DOI: 10.3390/jcm11133835.

References
1.
Nakazawa D, Masuda S, Tomaru U, Ishizu A . Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2018; 15(2):91-101. DOI: 10.1038/s41584-018-0145-y. View

2.
Shi L . Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int. 2017; 37(11):1779-1788. DOI: 10.1007/s00296-017-3818-y. View

3.
Watts R, Lane S, Bentham G, SCOTT D . Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000; 43(2):414-9. DOI: 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. View

4.
Monti S, Craven A, Klersy C, Montecucco C, Caporali R, Watts R . Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. Rheumatology (Oxford). 2020; 60(2):617-628. DOI: 10.1093/rheumatology/keaa215. View

5.
Chandran V, van der Heijde D, Fleischmann R, Lespessailles E, Helliwell P, Kameda H . Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1). Rheumatology (Oxford). 2020; 59(10):2774-2784. PMC: 7516094. DOI: 10.1093/rheumatology/kez684. View